Comparison of New-Onset Gout in Adults Prescribed Chlorthalidone vs Hydrochlorothiazide for Hypertension

Journal of Clinical Hypertension

Volumn 16, Issue 12, 2014, Pages 864-868

  Wilson, Liza ^a   Nair, Kavita V ^b   Saseen, Joseph J ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GOUT; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX; TREATMENT DURATION; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; COHORT STUDIES; DIURETICS; FEMALE; GOUT; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84919617251     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12413     Document Type: Article

References (30)

1. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2011;64:1431-1446.
2. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447-1461.
3. Zhu Y, Pandya BJ, Choi KH. Prevalence of gout in the US general population: the NHANES survey 2007-2008. In ISPOR 13th Annual European Congress. Prague, Czech Republic, 2010.
4. McAdams DeMarco MA, Maynard JW, Baer AN, Coresh J. Hypertension and the risk of incident gout in a population-based study: the Atherosclerosis Risk in Communities cohort. J Clin Hypertens. 2012;14:675-679.
5. Saseen JJ, Agashivala N, Allen RR, et al. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012;51:2004-2012.
6. Ernst ME, Clark EC. Gout and hyperuricemia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. New York, NY: McGraw-Hill; 2011:
7. IMS Institute for Healthcare Informatics. Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States in 2012. http://tinyurl.com/n8s8bs6. Accessed August, 2013.
8. Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med. 1991;90:50S-54S.
9. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
11. Rosei EA, Dal Palu C, Leonetti G, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens. 1997;15:1337-1344.
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
13. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20.
14. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
15. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153-2164.
16. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
17. Chronic Condition Indicator for ICD-9-CM. http://www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. Accessed June 25, 2014.
18. Kim SC, Schmidt BM, Franklin JM, et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Arthritis Care Res (Hoboken). 2013;65:2008-2014.
19. Wu EQ, Forsythe A, Guérin A, et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012;19:e157-e166.
20. Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology (Oxford). 2013;52:118-126.
21. Chandratre P, Roddy E, Clarson L, et al. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52:2031-2040.
22. Rothenbacher DL, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50:973-981.
23. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013;52:34-44.
24. Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, et al. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum. 2012;41:879-889.
25. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50:953-959.
26. Stamp L, Ha L, Searle M, et al. Gout in renal transplant recipients. Nephrology (Carlton). 2006;11:367-371.
27. McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64:121-129.
28. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case control study. Arthritis Rheumatol. 2014;66:185-196.
29. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59:1110-1117.
30. Kim SC, Schmidt BM, Franklin JM, et al. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res. 2013;65:2008-2014.